---
title: "The pharmaceutical sector rises, with multiple stocks hitting the daily limit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/233548434.md"
description: "The pharmaceutical sector surged, with multiple stocks such as BHC, HC CHEMICAL, and Rundu Pharma hitting the daily limit. ApicHope and Mabwell rose over 8%, while KHPG increased by more than 7%"
datetime: "2025-03-28T02:03:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/233548434.md)
  - [en](https://longbridge.com/en/news/233548434.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/233548434.md)
generator: "portal-rs"
---

# The pharmaceutical sector rises, with multiple stocks hitting the daily limit

The pharmaceutical sector surged, with multiple stocks such as BHC, HC CHEMICAL, and Rundu Pharma hitting the daily limit. ApicHope and Mabwell rose over 8%, while KHPG increased by more than 7%

### Related Stocks

- [600721.CN](https://longbridge.com/en/quote/600721.CN.md)
- [000953.CN](https://longbridge.com/en/quote/000953.CN.md)
- [002923.CN](https://longbridge.com/en/quote/002923.CN.md)
- [300723.CN](https://longbridge.com/en/quote/300723.CN.md)
- [688062.CN](https://longbridge.com/en/quote/688062.CN.md)
- [002773.CN](https://longbridge.com/en/quote/002773.CN.md)

## Related News & Research

- [Mabwell reports Phase Ib/IIa data showing anti-ST2 antibody 9MW1911 cuts COPD exacerbations up to 81%](https://longbridge.com/en/news/298042457.md)
- [Mabwell Reports Positive COPD Data for 9MW1911 Ahead of ERS 2026](https://longbridge.com/en/news/298058989.md)
- [Livzon Pharma Calls EGM to Approve Cross-Border Special Interim Dividend](https://longbridge.com/en/news/298301071.md)
- [CAMP: Phase I trial for SYNGAP1 to launch in Q4, leveraging global sites and robust preclinical data](https://longbridge.com/en/news/298494403.md)
- [Cytonics Completes $4.8 Million Gross-Proceeds Financing Campaign](https://longbridge.com/en/news/298484470.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**